The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

Anecdotal reports suggest drugs like Ozempic may curb not just appetite but also impulsive or addictive behaviour, hinting at ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Dear Dr. Roach: My 66-year-old husband recently received a diagnosis of heart failure with preserved ejection fraction. He is ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

There’s no question about the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, but some doctors are worried the ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

GLP-1s are driving traditional drug spending in the U.S. to unprecedented levels, which now outpaces specialty drug spending ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to ...

These drugs help people lose weight and have also been shown to reduce hospitalization for heart failure. Pancreatitis has been reported in people taking GLP-1 drugs.